Retatrutide and Gastroparesis: What Gastric-Emptying Research Shows
Compare retatrutide gastric-emptying measurements with gastroparesis diagnosis, including the actual study method and why completion counts are not a disease rate.
FormBlends Editorial Research · Updated 2026-10-03
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
Retatrutide delayed gastric emptying in a small mechanistic study. That result is different from a measured rate of clinically diagnosed gastroparesis. The study examined acetaminophen absorption; it did not report a solid-meal diagnostic test or a retatrutide gastroparesis incidence rate.
What the retatrutide study measured
Urva and colleagues, 2023, assessed gastric emptying within a phase 1b trial in adults with type 2 diabetes. Seventy-two participants received at least one study dose and 43 completed the study. The investigators measured acetaminophen concentrations before treatment and at Days 2, 30 and 79.
The greatest effect appeared after the first retatrutide dose and generally diminished at later measurements. In groups receiving at least 3 mg, the time to peak acetaminophen concentration was delayed by approximately one hour at Day 2 and remained delayed at later checks. Overall acetaminophen exposure was not affected.
The authors identify the small sample and indirect acetaminophen method as limitations. They did not use scintigraphy or breath testing, and called for confirmation with a solid meal. COVID-19 restrictions contributed substantially to study discontinuations.
Three questions that should stay separate
| Question | Evidence needed | What this study supplies |
|---|---|---|
| Does retatrutide affect emptying? | A specified gastric-emptying measurement and comparator | An indirect acetaminophen assessment |
| How often is gastroparesis diagnosed? | Defined diagnostic criteria, case counts, denominator and follow-up | No diagnosed-incidence estimate |
| How long does a person's symptom last? | Symptom-onset and resolution observations | Not an individual symptom timeline |
The ACG guideline defines gastroparesis using relevant symptoms plus objective evidence of delayed emptying without mechanical obstruction. A drug's effect on an absorption probe is not equivalent to establishing that diagnosis in every participant.
What does an approximately one-hour delay mean?
It refers to time to peak acetaminophen concentration in the study's specified groups and measurement. It does not mean the stomach was paralyzed for an hour, that solid food universally took an extra hour to empty, or that one hour is a diagnostic threshold.
The endpoints answer different questions: peak concentration concerns the height of the concentration curve; time to peak concerns timing; total exposure concerns its area. A change in one does not require the same change in the others.
Can we calculate a gastroparesis percentage from this study?
No. An incidence percentage requires diagnosed cases divided by a specified population over a specified period. The number 72 is the study population receiving at least one dose, not a gastroparesis case count. The number 43 is study completion, not recovery from gastroparesis.
Here is the interpretation check: 72 minus 43 equals 29 people who did not complete the study. Calling 29 divided by 72, or 40.3%, a gastroparesis rate would be wrong. The report identifies pandemic restrictions as the most common discontinuation reason.
Does a diminishing effect prove the risk disappears?
A smaller later effect on the absorption measurement describes the measured time course. It does not establish that every participant's symptoms resolve or that a clinical condition cannot occur. Mechanistic adaptation and a diagnosed disease rate are separate endpoints.
Frequently asked questions
Is there direct retatrutide gastric-emptying research?
Yes. The 2023 study measured an indirect acetaminophen absorption response within a phase 1b trial.
Does it prove a specific gastroparesis risk percentage?
No. It does not provide the diagnosed case count needed for that calculation.
Can nausea alone establish gastroparesis?
No. A symptom term and the objective diagnostic evidence specified by the guideline are different information.
The cited research does not establish a personalized prediction, a proven symptom timeline or a home management protocol for the concern in this article. Physician supervision does not turn an investigational substance into an FDA-approved treatment. Participants should report adverse events to their study team rather than infer a dosing change from an article.